TrialArthritis research & therapy2011

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments.

Heleen Scheerens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.